Myasthenia Gravis – Epidemiology – Mature Markets

Clarivate Epidemiology’s coverage of myasthenia gravis (MG) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of MG for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s MG forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of MG over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts five MG patient populations in the major mature pharmaceutical markets, as follows:

  • Diagnosed prevalent cases of MG.
  • Diagnosed prevalent cases of ocular MG.
  • Diagnosed prevalent cases of generalized MG.
  • Diagnosed prevalent cases of anti-AChR-seropositive MG.
  • Diagnosed prevalent cases of thymoma MG.

Note: Coverage may vary by country.